Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): Price and Financial Metrics

Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB): $2.37

-0.01 (-0.42%)

POWR Rating

Component Grades














  • TRIB scores best on the Value dimension, with a Value rank ahead of 99.85% of US stocks.
  • TRIB's strongest trending metric is Momentum; it's been moving down over the last 43 weeks.
  • TRIB's current lowest rank is in the Momentum metric (where it is better than 15.47% of US stocks).

TRIB Stock Summary

  • TRIB has a market capitalization of $49,746,052 -- more than approximately only 6.01% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for TRIB is -45.96 -- better than just 0.43% of US stocks.
  • TRIB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.66% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Trinity Biotech Plc, a group of peers worth examining would be EVRI, VEON, BAK, MAS, and LTMAQ.
  • Visit TRIB's SEC page to see the company's official filings. To visit the company's web site, go to

TRIB Valuation Summary

  • TRIB's price/earnings ratio is -8.5; this is 123.29% lower than that of the median Healthcare stock.
  • TRIB's EV/EBIT ratio has moved down 502.7 over the prior 243 months.
  • Over the past 243 months, TRIB's price/earnings ratio has gone down 11.6.

Below are key valuation metrics over time for TRIB.

Stock Date P/S P/B P/E EV/EBIT
TRIB 2021-08-31 0.5 -24.6 -8.5 -500.8
TRIB 2021-08-30 0.5 -24.9 -8.6 -503.1
TRIB 2021-08-27 0.6 -25.5 -8.9 -508.6
TRIB 2021-08-26 0.5 -24.6 -8.5 -500.8
TRIB 2021-08-25 0.5 -25.2 -8.8 -506.2
TRIB 2021-08-24 0.5 -25.2 -8.8 -506.2

TRIB Growth Metrics

  • Its year over year revenue growth rate is now at 12.77%.
  • The year over year price growth rate now stands at 63.03%.
  • Its 3 year revenue growth rate is now at -9.21%.
Over the past 61 months, TRIB's revenue has gone up $1,785,000.

The table below shows TRIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 101.98 24.671 -6.388
2019-12-31 90.435 5.875 -28.914
2018-12-31 97.035 5.978 -22.09
2017-12-31 99.14 9.37 -40.27
2016-12-31 99.611 10.556 -100.625
2015-12-31 100.195 13.518 21.796

TRIB Stock Price Chart Interactive Chart >

Price chart for TRIB

TRIB Price/Volume Stats

Current price $2.37 52-week high $6.82
Prev. close $2.38 52-week low $1.75
Day low $2.28 Volume 157,800
Day high $2.42 Avg. volume 336,715
50-day MA $2.33 Dividend yield N/A
200-day MA $3.61 Market Cap 49.54M

Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB) Company Bio

Trinity Biotech plc develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The company was founded in 1992 and is based in Bray, Ireland.

TRIB Latest News Stream

Event/Time News Detail
Loading, please wait...

TRIB Latest Social Stream

Loading social stream, please wait...

View Full TRIB Social Stream

Latest TRIB News From Around the Web

Below are the latest news stories about Trinity Biotech Plc that investors may wish to consider to help them evaluate TRIB as an investment opportunity.

35 Stocks Moving In Thursday's Mid-Day Session

Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE: OPAD) surged 35.3% to $15.62. Torrid Holdings Inc. (NYSE: CURV) shares gained 26.1% to $23.29 after the company reported better-than-expected Q2 EPS and sales results. Torrid sees Q3 sales of $305 million - $315 million, above the consensus of $294.74 million. The company expects FY21 sales of $1.29 billion - $1.31 billio

Yahoo | September 9, 2021

Trinity Biotech Announces Results for Q2, 2021

DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021. Quarter 2 ResultsTotal revenues for Q2, 2021 were $25.8m, which compares to $16.0m in Q2, 2020, an increase of $9.8m and which were broken down as follows: 2020Quarter 22021Quarter 2 Increase US$’000US$’000%Point-of-Care1,2671,95854.5%

Yahoo | September 9, 2021

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2021 Financial Results

Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN

Intrado Digital Media | August 31, 2021

At 6.8% CAGR, Antiviral Drug Resistance Market is Projected to Surpass US$ 4,573.24 million by 2027 Rise in Prevalence of Virus infections such as Hepatitis Diseases to Drive the Market | Trinity Biotech, AccuBioTech Co., Ltd., and ACON Laboratories, Inc.

The antiviral drug resistance market was valued at US$ 2,572.26 million in 2018 and it is projected to reach US$ 4,573.24 million in 2027; it is expected to grow at a CAGR of 6.8% from 2019 to 2027. Antiviral drug resistance

OpenPR | August 26, 2021

Antinuclear Antibody Test Market Growth By 2025| ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.)

Antinuclear Antibody Test Market analysis provides an examination of various segments that are supposed to witness the quickest development amid the estimated forecast frame. The market study of this report takes into consideration market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. This market research report []

Jumbo News | August 23, 2021

Read More 'TRIB' Stories Here

TRIB Price Returns

1-mo -1.25%
3-mo -14.44%
6-mo -42.89%
1-year 1.28%
3-year -39.54%
5-year -81.41%
YTD -37.80%
2020 268.69%
2019 -54.87%
2018 -55.10%
2017 -26.30%
2016 -41.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.6125 seconds.